DE10105040A1 - Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems - Google Patents
Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des NervensystemsInfo
- Publication number
- DE10105040A1 DE10105040A1 DE10105040A DE10105040A DE10105040A1 DE 10105040 A1 DE10105040 A1 DE 10105040A1 DE 10105040 A DE10105040 A DE 10105040A DE 10105040 A DE10105040 A DE 10105040A DE 10105040 A1 DE10105040 A1 DE 10105040A1
- Authority
- DE
- Germany
- Prior art keywords
- alkoxy
- alkyl
- group
- derived
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 7
- 210000000653 nervous system Anatomy 0.000 title claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 21
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 21
- 150000001413 amino acids Chemical class 0.000 claims abstract description 14
- 125000005843 halogen group Chemical group 0.000 claims abstract description 9
- -1 cinnamoyl residue Chemical group 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 abstract description 5
- 230000000302 ischemic effect Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- 241000024188 Andala Species 0.000 abstract 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 16
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 9
- 102000007072 Nerve Growth Factors Human genes 0.000 description 9
- 102000015336 Nerve Growth Factor Human genes 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 210000001787 dendrite Anatomy 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 239000003900 neurotrophic factor Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 2
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 102000004230 Neurotrophin 3 Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 230000003018 neuroregenerative effect Effects 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 229940097998 neurotrophin 4 Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 102000038778 CNTF family Human genes 0.000 description 1
- 108091064557 CNTF family Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710154250 Small basic protein Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10105040A DE10105040A1 (de) | 2001-02-05 | 2001-02-05 | Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems |
| DK02704686T DK1390055T3 (da) | 2001-02-05 | 2002-02-05 | Tripeptidderivater til behandling af postlæsionale lidelser i nervesystemet |
| JP2002562378A JP2004526701A (ja) | 2001-02-05 | 2002-02-05 | 神経系の損傷後疾患の処置のためのトリペプチド誘導体 |
| ES02704686T ES2250617T3 (es) | 2001-02-05 | 2002-02-05 | Derivados de tripeptidos para el tratamiento de enfermedades postlesion del sistema nervioso. |
| AT02704686T ATE310529T1 (de) | 2001-02-05 | 2002-02-05 | Tripeptidderivate zur behandlung von postläsionalen krankheiten des nervensystems |
| EP02704686A EP1390055B1 (en) | 2001-02-05 | 2002-02-05 | Tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
| PCT/EP2002/001182 WO2002062372A2 (en) | 2001-02-05 | 2002-02-05 | Tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
| DE60207550T DE60207550T2 (de) | 2001-02-05 | 2002-02-05 | Tripeptidderivate zur behandlung von postläsionalen krankheiten des nervensystems |
| AU2002238532A AU2002238532A1 (en) | 2001-02-05 | 2002-02-05 | Tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
| US10/635,808 US7163922B2 (en) | 2001-02-05 | 2003-08-05 | Tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10105040A DE10105040A1 (de) | 2001-02-05 | 2001-02-05 | Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10105040A1 true DE10105040A1 (de) | 2002-08-14 |
Family
ID=7672833
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10105040A Ceased DE10105040A1 (de) | 2001-02-05 | 2001-02-05 | Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems |
| DE60207550T Expired - Lifetime DE60207550T2 (de) | 2001-02-05 | 2002-02-05 | Tripeptidderivate zur behandlung von postläsionalen krankheiten des nervensystems |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60207550T Expired - Lifetime DE60207550T2 (de) | 2001-02-05 | 2002-02-05 | Tripeptidderivate zur behandlung von postläsionalen krankheiten des nervensystems |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7163922B2 (enExample) |
| EP (1) | EP1390055B1 (enExample) |
| JP (1) | JP2004526701A (enExample) |
| AT (1) | ATE310529T1 (enExample) |
| AU (1) | AU2002238532A1 (enExample) |
| DE (2) | DE10105040A1 (enExample) |
| DK (1) | DK1390055T3 (enExample) |
| ES (1) | ES2250617T3 (enExample) |
| WO (1) | WO2002062372A2 (enExample) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0316218B1 (fr) * | 1987-11-03 | 1993-09-15 | EKITA Investments N.V. | Nouveaux dérivés de l-proline, leur préparation et leurs applications biologiques |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU599809B2 (en) * | 1987-05-20 | 1990-07-26 | Zambon Group S.P.A. | Isoxazoles with nootropic activity |
| CA1323301C (en) | 1987-06-05 | 1993-10-19 | Alan I. Faden | Thyrotropin-releasing hormone analogs in cns injury |
| HU904967D0 (en) * | 1988-04-22 | 1991-01-28 | Hoechst Ag | Process for producing new azabicyclo(3.3.o)octane-3-carboxylic acid-octylesther derivatives |
| DE4007869A1 (de) | 1990-03-13 | 1991-09-19 | Merck Patent Gmbh | Aminosaeurederivate |
| JPH045240A (ja) | 1990-04-20 | 1992-01-09 | Taisho Pharmaceut Co Ltd | 抗痴呆剤 |
| JPH06504061A (ja) | 1990-12-28 | 1994-05-12 | コーテックス ファーマシューティカルズ インコーポレイテッド | 神経変性の治療および予防におけるカルパイン阻害剤の使用 |
| WO1992013549A1 (en) * | 1991-02-07 | 1992-08-20 | Research Corporation Technologies, Inc. | Inhibition of cell proliferation by hydrophobic peptides |
| US6235929B1 (en) * | 1991-12-27 | 2001-05-22 | Georgia Tech Research Corporation | Tripeptide α-ketoamides |
| US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5834029A (en) * | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
| EP0840614A1 (en) | 1995-06-13 | 1998-05-13 | Sanofi Winthrop, Inc. | Calpain inhibitors for the treatment of neurodegenerative diseases |
| US5840838A (en) * | 1996-02-29 | 1998-11-24 | University Of Kentucky Research Foundation | Process for enhancing the activity of amyloid β peptides |
| JP2001501930A (ja) | 1996-10-04 | 2001-02-13 | オークランド ユニサーヴィスィズ リミテッド | 神経酵素の調節 |
| JP4727770B2 (ja) * | 1997-09-26 | 2011-07-20 | カルピス株式会社 | 尿中カテコールアミン低下、尿中ノルアドレナリン低下、尿中ドーパミン低下及びＦｉｓｃｈｅｒ比低下の少なくとも１つの軽減剤 |
| US6080848A (en) * | 1998-05-01 | 2000-06-27 | Incyte Pharmaceuticals, Inc. | Human brain associated protein |
| US6379691B1 (en) * | 1998-09-29 | 2002-04-30 | Medtronic/Ave, Inc. | Uses for medical devices having a lubricious, nitric oxide-releasing coating |
| AU1574701A (en) * | 1999-10-22 | 2001-04-30 | Wrair Walter Reed Army Institute Of Research | A pharmaceutical composition containing pglu-glu-pro-nh2 and method for treating diseases and injuries to the brain, spinal cord and retina using same |
| JP4633876B2 (ja) * | 1999-11-11 | 2011-02-16 | カルピス株式会社 | トリペプチドの製造方法 |
| WO2001068114A1 (en) | 2000-03-10 | 2001-09-20 | Monsanto Company | Novel peptides with anti-hypertensive activity |
| DE10105041A1 (de) * | 2001-02-05 | 2002-08-14 | Tell Pharm Ag Hergiswil | Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten |
| DE10105038B4 (de) * | 2001-02-05 | 2005-07-07 | Neurotell Ag | Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems |
-
2001
- 2001-02-05 DE DE10105040A patent/DE10105040A1/de not_active Ceased
-
2002
- 2002-02-05 AU AU2002238532A patent/AU2002238532A1/en not_active Abandoned
- 2002-02-05 JP JP2002562378A patent/JP2004526701A/ja active Pending
- 2002-02-05 DE DE60207550T patent/DE60207550T2/de not_active Expired - Lifetime
- 2002-02-05 DK DK02704686T patent/DK1390055T3/da active
- 2002-02-05 EP EP02704686A patent/EP1390055B1/en not_active Expired - Lifetime
- 2002-02-05 ES ES02704686T patent/ES2250617T3/es not_active Expired - Lifetime
- 2002-02-05 AT AT02704686T patent/ATE310529T1/de not_active IP Right Cessation
- 2002-02-05 WO PCT/EP2002/001182 patent/WO2002062372A2/en not_active Ceased
-
2003
- 2003-08-05 US US10/635,808 patent/US7163922B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0316218B1 (fr) * | 1987-11-03 | 1993-09-15 | EKITA Investments N.V. | Nouveaux dérivés de l-proline, leur préparation et leurs applications biologiques |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE310529T1 (de) | 2005-12-15 |
| AU2002238532A1 (en) | 2002-08-19 |
| EP1390055A2 (en) | 2004-02-25 |
| EP1390055B1 (en) | 2005-11-23 |
| DK1390055T3 (da) | 2006-01-09 |
| US7163922B2 (en) | 2007-01-16 |
| JP2004526701A (ja) | 2004-09-02 |
| DE60207550T2 (de) | 2006-08-10 |
| ES2250617T3 (es) | 2006-04-16 |
| WO2002062372A3 (en) | 2004-01-08 |
| DE60207550D1 (de) | 2005-12-29 |
| US20050101539A1 (en) | 2005-05-12 |
| WO2002062372A2 (en) | 2002-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3786250T2 (de) | Phosphinsäure-Derivate. | |
| DE69024965T2 (de) | Dehydrodidemnin b | |
| DE3876400T2 (de) | Aminosaeure-imid-derivate, ihre verwendung und diese enthaltende medizinische zusammensetzungen. | |
| DE2602193A1 (de) | Peptid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| DE3122479A1 (de) | N-(vinblastin-23-oyl)-aminosaeurederivate | |
| EP0610487A1 (de) | Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
| EP0490379A2 (de) | Diaminosäurederivate und pharmazeutische Zusammensetzungen | |
| EP0484719A2 (de) | Tachykinin antagonist | |
| EP0934329A1 (de) | Glycokonjugate von modifizierten camptothecin-derivaten (20-o-verknüpfung) | |
| DE60133654T2 (de) | Arzneimittel enthaltend analgetische peptide | |
| DE60007345T2 (de) | Basische monocyclische verbindungen mit nk-2 antagonistischer wirkung, verfahren zu ihrer herstellung, und sie enthaltende mittel | |
| CH649562A5 (de) | Derivate des methionin-enzephalins. | |
| DE60215917T2 (de) | Tripepide und tripepdid-derivte zur behandlung von neurodegenerativen erkrankungen | |
| DE10105038B4 (de) | Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems | |
| DE10105040A1 (de) | Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems | |
| DE69425734T2 (de) | Aureobasidine | |
| DE2112057A1 (de) | Neue Penicillinester | |
| DE69120024T2 (de) | Neovascularisationsinhibitoren | |
| DE60307049T2 (de) | Verwendung von Piperazin- Phenothiazin- Derivaten zur Herstellung eines Arzneimittels mit neuroprotektiven und/oder neurotropischen Wirkungen auf das ZNS und/oder PNS | |
| DE69307414T2 (de) | Dipeptidderivate und diese als aktive Bestandteile enthaltendes prophylaktisches oder therapeutisches Mittel gegen Knochenkrankheiten | |
| DE69615845T2 (de) | Polycyclische alkaloid-derivate als nmda-rezeptor-antagonisten | |
| DE10105039A1 (de) | Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten | |
| EP0028716A2 (de) | Motilitätssteigernde Peptide und deren Verwendung | |
| EP0338508A2 (de) | Aminosäureester, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und deren Verwendung | |
| DE1805280C3 (de) | Verfahren zur Herstellung von Cyclopeptiden, bestimmte Cyclopeptide und diese enthaltende pharmazeutische Zusammensetzungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8131 | Rejection |